Kornimate/medical-research-clean huggingface dataset:
a smartphone intervention for relational and mental well being

Conditions: Depression; Loneliness; Relation, Interpersonal; Covid19

Summary: the primary aim of this study is to provide and evaluate a phone-based intervention to improve relational and mental well-being during the covid-19 crisis. this information also will help us understand how individuals are responding to covid-19 and have the potential to inform psychological and policy level interventions.

we conducted a randomized intervention trial of a mobile-based intervention that offered participants daily suggestions for 14 days on how to improve relational and mental well-being during the covid-19 pandemic. a sample of 1765 adults residing in the united states participated in the study and were assigned to control or intervention conditions. to measure outcomes, all participants received a daily text message to their smartphones every evening for 28 days linking to a survey on relational and mental well-being. participants also received a survey link on days 56 and 72. intervention participants received additional text messages in the mornings of days 7 - 22 presenting the intervention suggestions.

Eligibility criteria:
inclusion criteria: * age 18+ * resides in united states * possesses smartphone * willing to share phone number and email to researchers exclusion criteria: * none
cmf bone stimulation as adjunct to surgical treatment of ankle fractures

Conditions: Bimalleolar Ankle Fractures

Summary: the ol1000 is intended to be used as a non-invasive adjunctive treatment for adult males or females that have sustained a closed, unstable ankle fracture that requires surgical treatment for stabilization. the initiation of the adjunctive treatment is to begin within 11 days of surgical stabilization.


Eligibility criteria:
inclusion criteria: * subject is diagnosed with an unstable, closed, isolated fracture of the ankle and underwent operative stabilization with plate(s) and/or screws (weber ankle fracture classification b and c) exclusion criteria: * subject has an open fracture * subject has any additional fractures of another bone besides the ankle fracture that is to be treated in the study including the contralateral ankle * surgical stabilization was definitively performed with an external fixation system * surgical stabilization was performed in such a manner that it will result in a fusion of the ankle joint * malreduced ankle as described by phillips, et al 1985 jbjs * surgical procedure included the use of osteoinductive materials in addition to rigid fixation * bmi ≥ 40 kg/m2

Keywords: bone growth stimulator ankle fracture
hypothermia in acute stroke with thrombolysis imaging evaluation of revascularization

Conditions: Acute Ischemic Stroke

Summary: the primary objective of this phase 2 hastier study, as an ancillary study to ictus 2, is to compare key imaging measurements for serial changes in recanalization and reperfusion between hypothermia and normothermia treatment arms as intermediate outcomes of treatment effect. secondary exploratory analyses include imaging of the neurovascular impact of reperfusion with hypothermia and tpa, including blood-brain barrier changes or permeability, hemorrhagic transformation, and infarct growth.

a prospective imaging ancillary study coincides with recruitment of ictus 2 by using currently available imaging tools at a subset of multicenter sites. hastier will evaluate therapeutic response with imaging outcome measures for recanalization and reperfusion. key scientific objectives include the evaluation of hypothermia on benchmark recanalization and reperfusion rates in 120 cases of middle cerebral artery (mca) stroke. recanalization will be measured with thrombolysis in myocardial infarction (timi) score change from baseline-36 hour ct/mri angiography. reperfusion will be measured with tmax \> 6s lesion volume change from baseline-36 hour ct/mri perfusion imaging. secondary outcomes will be measured with serial changes in permeability abnormalities derived from ct/mri perfusion imaging, hemorrhagic transformation, and infarct growth from baseline-36 hours. correlation of these imaging parameters with clinical outcomes will provide insight to accelerate research during these translational steps in hypothermia treatment for acute ischemic stroke.

Eligibility criteria:
inclusion criteria: * eligible for inclusion in the ictus 2/3 trial. * diagnosis of mca stroke, confirmed by m1 or m2 proximal mca occlusion on ct/mri angiography. exclusion criteria: * kidney dysfunction of such severity as to preclude routine administration of contrast media for ct/mri angiography or perfusion imaging. severe kidney dysfunction is defined by the american college of radiology recommendations for use of contrast media. * known adverse reaction or allergy to such contrast media.

Keywords: stroke hypothermia thrombolysis imaging collateral circulation recanalization reperfusion
neurocontrol of nicotine dependence

Conditions: Nicotine Dependence

Summary: the purpose of the study is to examine the effects of continuous theta burst stimulation (ctbs) on different forms of cognitive control in adults who smoke cigarettes, and to determine if the location where ctbs is delivered may help smokers reduce or quit smoking. participation in the study will take 3-weeks over 4 visits, with a total time commitment of approximately 12 hours.


Eligibility criteria:
inclusion criteria: 1. nicotine dependence as measured by: smoke ≥ 8 cigarettes/day for ≥ 2 yrs, expired carbon monoxide (co) concentration of ≥ 10 ppm, positive urine cotinine test and ftnd score ≥ 3 or ≥ 15 uses of electronic cigarette/day for ≥ 1 year, positive urine cotinine test, and ps-ecdi score ≥ 3 2. english fluency 3. functional vision (with corrective lenses as needed) exclusion criteria: 1. use of psychotropic and antiepileptic medications in the last month 2. presence of an untreated illness or serious medical condition 3. history of major neurological illness 4. contraindication to tms (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for \>15 min., implanted electronic device, metal in the head) or mri. 5. any use of substances that lower seizure threshold. 6. current or past psychosis 7. electroconvulsive therapy in the past 6 months 8. unstable cardiac disease or hypertension, severe renal or liver insufficiency, or sleep apnea 9. bac greater than 0.0. 10. positive urine pregnancy test 11. any other concern that in the investigator's opinion would impact participant safety, study instruction compliance, or confound the interpretation of the study results.

Keywords: tobacco smoking tms fmri nicotine cognitive control
quality of image and performance diagnoses of the 3d sequence of cholangio-pancreatography mri in apnea with compressed acquisition

Conditions: Cholangiopancreatography

Summary: the sequence of 3d cp-irm, used in current practice in the protocols of bilio-pancreatic imaging, can be thus optimized to reduce acquisition time, thus the artefacts of movement, in particular in 3t. it remains however to estimate if the quality of obtained image is equivalent at least to that of the conventional sequence, without apnea, 3d cp-irm. to summarize, the investigators suggest comparing the classic sequence (fast relaxation fast spin echo (frfse) 3d) already existing with the same sequence to which will be added a technique of cs allowing its acquisition at shortened time(weather), with respiratory trigger on one hand and in apnea on the other hand. for the patient, this study will have for consequence only the addition of 2 sequence mri, one of the 2 minutes 30 seconds (with respiratory trigger) and other one of the 20 seconds (in apnea).


Eligibility criteria:
inclusion criteria: * age\> 18 * french understanding and speaking patient * pancreatic mri prescription for bilio-pancreatic pathology * patient with medical insurance exclusion criteria: * previous biliary surgery * mri contraindication * gadolinium recently injected (48 hours) * patient couldn't stay on apnea 20 seconds
a phase i study to evaluate gfs202a in advanced solid tumor patients with pre-cachexia or cachexia

Conditions: Cancer Cachexia

Summary: an open-label, multi-center, phase i study to evaluate the safety/tolerability and pharmacokinetics of gfs202a in advanced solid tumor patients with pre-cachexia or cachexia. the primary objective is to assess the safety/tolerability of gfs202a, determine its maximum tolerated dose (mtd), and recommend a dose range for future studies. enroll participants with cancer cachexia or precachexia to receive gfs202a monotherapy. during the study period, participants will undergo assessments for safety and preliminary efficacy according to the visit schedule. pharmacokinetic, anti-drug antibody (ada), and pharmacodynamic (pd) /biomarker samples will be collected.


Eligibility criteria:
inclusion criteria: 1. voluntarily participate in the study and sign the informed consent form. 2. men or women between the ages of 18 and 80 years at the time of written informed consent. 3. patients with histologically or cytologically confirmed solid tumors. pre-cachectic and cachectic patients with weight loss or baseline bmi \< 21 kg/m2 within 6 months before the first study dose. 4. persistent concomitant appetite/eating problems related to cancer. 5. it has adequate organ function. 6. the ecog ps score was 0-2. 7. the investigator judged the expected survival time to be ≥ 3 months. exclusion criteria: 1. with active brain metastases. 2. with other active diseases that lead to reduced food intake or seriously affect digestion and absorption 3. baseline bmi \> 28 kg/m2. 4. with infectious diseases. 5. with clinically significant cardiovascular disease. 6. with uncontrolled metabolic diseases. 7. with known clinically significant allergic reactions to antibodies and excipients. 8. with history of drug or alcohol abuse. 9. pregnant or lactating female subjects or women planning to become pregnant during the study. 10. with pleural, peritoneal, or pericardial effusion that causes overt symptoms or requires repeated drainage (frequency ≥ 1 time/month). 11. use of any investigational drug within 28 days before the first study dose or within five half-lives of the drug, whichever was shorter, or planned for the duration of the study.

Keywords: cachexia cancer gdf-15 il-6
prevention of irinotecan induced diarrhea by probiotics

Conditions: Colorectal Cancer

Summary: irinotecan is one of key drug used in the treatment of colorectal cancer. the incidence of irinotecan induced diarrhea varies between 60-90%, with severe diarrhea in 20-40%. the main cause of diarrhea is one of irinotecan metabolites, sn-38 which is in the liver glucuronidated and subsequently expelled into the intestine. due to the bacterial enzyme beta-d-glucuronidase in intestinal lumen it is deconjugated. this form causes direct damage of intestinal mucosa associated with malabsorption and the development of diarrhea. it is known that probiotic bacteria, reduce activity of intestinal beta-d-glucuronidase and therefore these bacteria could be applied in the prevention of diarrhea in patients treated by this food supplement. given their low toxicity, good tolerability, probiotics may be an important part of supportive therapy. this is a first study aimed to determine the effectiveness of the probiotics in the prophylaxis of irinotecan induced diarrhea due to reduction intestinal beta-d-glucuronidase activity.


Eligibility criteria:
inclusion criteria: * signed written informed consent * histologically proven colorectal cancer patients started new line of chemotherapy based on irinotecan * ecog ps 0 - 1 at study entry * life expectancy more than 3 months * absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; exclusion criteria: * impossibility to take oral medication * active infection treated by antibiotic therapy * ileostomy * hypersensitivity to study drug * any concurrent malignancy other than non-melanoma skin cancer, no other cancer in past 5 years. * serious concomitant systemic disorders or diseases incompatible with the study (at the discretion of investigator )

Keywords: probiotics diarrhoea prevention colon cancer irinotecan
enzastaurin plus fulvestrant vs. placebo plus fulvestrant in breast cancer

Conditions: Breast Cancer

Summary: the primary purpose of this study is to help answer the following research question: whether enzastaurin given together with fulvestrant can help participants who have breast cancer and make the tumor smaller or disappear and for how long.


Eligibility criteria:
inclusion criteria: * female participants with a histological-documented diagnosis of locally advanced or metastatic breast cancer. the primary or metastatic tumor must be estrogen response (er) and/or parathyroid hormone receptor (ptr) positive. note: hormone receptor positivity is defined as er or ptr greater than 10 fmol/mg by biochemical assay or 10% positive cells by immunohistochemistry * participants are resistant to aromatase inhibitors (ai) therapy * females with postmenopausal status * previous radiation therapy is allowed, but should have been limited * measurable or non-measurable disease * have a performance status of 0, 1, or 2 on the eastern cooperative oncology group (ecog) scale * have adequate organ function * have an estimated life expectancy of at least 24 weeks * must sign an informed consent document exclusion criteria: * have had prior treatment with fulvestrant or enzastaurin * are receiving concurrent administration of any other antitumor therapy, with the exception of gonadotropin-releasing hormone (gnrh) antagonists. * have received treatment within the last 4 weeks with a drug that has not received regulatory approval for any indication at the time of study entry * have received supplemental estrogen or progesterone within 4 weeks prior to study entry * are hormone estrogen receptor (her2)-positive * are unable to discontinue use of anticoagulants * have hypercalcemia * have a second primary malignancy that is clinically detectable at the time of consideration for study enrollment * have documented central nervous system (cns) metastases, symptomatic pulmonary lymphangitis, or involvement of more than 1/3 of the liver * have a serious concomitant systemic disorder * have a serious cardiac condition * are unwilling or unable to discontinue use of carbamazepine, phenobarbital, or phenytoin at least 14 days prior to study therapy * are unable to swallow tablets.
facilitating use of the national suicide prevention lifeline in alcohol patients (reach out)

Conditions: Suicide; Alcohol Use Disorder

Summary: the purpose of this research study is to learn about people who use the national suicide prevention (nsp) lifeline during a suicidal crisis and those who don't. the researchers would also like to learn whether people who have experienced a suicidal crisis could benefit from participating in a therapy session about their thoughts and perceptions of the nsp lifeline.


Eligibility criteria:
inclusion criteria: * probable alcohol use disorder within the past year based on an alcohol use disorders identification test (audit) score of 16 or greater * report of a suicide attempt within the past year or a lifetime suicide attempt more than a year ago and current suicide ideation within the past month based on a score of 5 or greater on the beck scale for suicidal ideation (bss) or depression in the past month as measured by the beck depression inventory with a of 20 or higher. exclusion criteria: * patients who do not understand english * prisoners * patients with profound psychotic symptoms and/or cognitive deficits that would prevent patients from understanding the content of the intervention and/or assessments.

Keywords: national suicide prevention lifeline
endoscopic band ligation for treating reflux disease

Conditions: GERD

Summary: gerd is a chronic disease the require different treatment modalities; non have proven long term efficacy with concerns about their safety. the use of band ligation in endoscopy appears safe, repeatable with short learning curve. placing multiple bands at the z-line can create a fibrous ring in the distal esophagus acting as a barrier against reflux of gastric content.

the aim of the study is the complete resolution of reflux symptoms without the use of any drug.

Eligibility criteria:
inclusion criteria: * symptomatic gerd exclusion criteria: * any previous surgery for gerd

Keywords: gerd gastroesophageal reflux band ligation endoband
moca vs. mms: which tool to detect cognitive disorders in oncogeriatric?

Conditions: Neoplasms

Summary: this study concerns elderly patients with cancer with onco-geriatric assessment. this study propose to associate the collection of the results with the mini-cog and the codex with the passing of the moca and the mms tests, as well as a neuropsychological assessment, in order to determine if the patients have cognitive impairments, to evaluate the sensitivity of these 4 screening tests in elderly patients seeking treatment for their cancer. the results of this study will make it possible, where appropriate, to adapt the practice in the context of oncogeriatric assessment.


Eligibility criteria:
inclusion criteria: * patient aged over 70 years * patient with cancer (solid tumor or haemopathy) for whom a first line treatment is envisaged (whatever it is). surgery and radiotherapy are allowed before entry into the study. * patient candidate for oncogeriatric assessment * patient agree to participate in the study * using the french language exclusion criteria: * primary central nervous system or cerebral metastasis * evolutionary psychiatric pathology known (e.g. schizophrenia) * severe visual and / or auditory impairment * patients unable to respond to cognitive tests * patient (s) deprived of liberty, under guardianship or curatorship * refusal of participation

Keywords: oncogeriatric mms moca
investigation of a novel gene expression test (asges or corus cad) for diagnosis of obstructive coronary artery disease

Conditions: Coronary Artery Disease; Angina Pectoris; Chest Pain; Cardiovascular Diseases; Coronary Heart Disease; CAD; CVD; CHD

Summary: the objective of this study is to collect data on the commercial use of corus cad (age/sex/gene expression score - asges) blood test to evaluate the clinical referral patterns of primary care physicians after receipt of their patients' corus score, and to better understand patient management patterns for clinicians ordering the test.

this is a prospective, multicenter observational registry collecting and analyzing commercial utilization data of the corus cad assay ("test") also known as age/sex/gene expression score (asges) . the study will prospectively enroll approximately 670 evaluable subjects from qualified sites and evaluate the rate of referral versus corus cad (asges) score as continuous variables. objective of the study is to assess whether the score provided by the corus cad (age/sex/gene expression score - asges) test has an effect on the primary care physician's patient management and referral patterns once received: 1. no further cardiac testing or treatment 2. medical therapy for angina or non-cardiac chest pain 3. referral to a cardiologist for stress testing with or without imaging, ct angiography, or invasive cardiac catheterization. since it takes approximately two days for the physician to receive the result of the corus cad (age/sex/gene expression score - asges) , initial diagnostic testing will reflect local standard of care.

Eligibility criteria:
inclusion criteria: 1. patients with symptoms suggestive of cad, including typical or atypical angina or angina equivalent 2. the patient has signed the appropriate institutional review board approved informed consent form exclusion criteria: 1. history of myocardial infarction 2. current mi or acute coronary syndrome 3. current new york heart association (nyha) class iii or iv congestive heart failure symptoms 4. any previous coronary revascularization 5. any individuals with: * diabetes * suspected unstable angina * systemic infections * systemic inflammatory conditions 6. any individuals currently taking: * steroids * immunosuppressive agents * chemotherapeutic agents 7. recipient of any organ transplant

Keywords: corus cad asges age/sex/gene expression score gene expression ges cad cvd chd precision medicine clinical utility registry coronary artery disease coronary heart disease cardiovascular disease angina pectoris chest pain registry i registry-i
tobacco smoking among crosslinked-keratoconus patients

Conditions: Keratoconus

Summary: certain studies reported that cigarette by-products may make the cornea more rigid, suggesting that it could lead to "natural" cxl of collagen fibers, hence a protective effect for kc. others have reported that cigarette smoking causes no significant changes in the corneal biomechanics. the aim of this study was to assess a possible link between keratoconus (kc) occurrence and patients' smoking habits.

a telephone survey was performed among 80 kc patients who were treated from march 2014 until september 2017 by accelerated crosslinking (a-cxl) within the ophthalmology department. from the 80 people we phoned, 62 answered. our questions were regarding family history, allergic history, and smoking habits. family history was considered positive if a first-degree or second-degree relative had been diagnosed with kc. allergies toward any kind of external factors were marked as positive. patients' smoking habits were recorded and classified into regular, occasional, ex-smoker and non-smoker. the results were confronted to those of the general population by indirect standardization over age and sex according to the "baromètre santé 2010" inpes survey (french nation institute for prevention and health education).

Eligibility criteria:
inclusion criteria: * patients suffering from keratoconus and needing cross-linking therapy exclusion criteria: * none